Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NXP900 + osimertinib
- Development stage
- Phase 1
- Lead developer
- Nuvectis Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NXP900 + osimertinib (Tagrisso) is an investigational drug combination consisting of NXP900, an oral small-molecule inhibitor of the SRC Family of Kinases (SFK), and osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. NXP900 uniquely locks SRC and YES1 kinases in their inactive, closed conformation, thereby inhibiting both their catalytic and scaffolding functions. This complete pathway shutdown is designed to overcome acquired resistance to EGFR inhibitors. Osimertinib is widely used to treat EGFR-mutated non-small cell lung cancer (NSCLC). The combination of NXP900 and osimertinib is being developed by Nuvectis Pharma and is currently in Phase 1b clinical trials for patients with advanced, EGFR-mutated NSCLC who have developed resistance to prior osimertinib therapy.
- Other names
- AZD9291 + eCF506AZD9291 + NXP900eCF506 + AZD9291eCF506 + osimertinibeCF506 + TagrissoNXP900 + AZD9291NXP900 + Tagrissoosimertinib + eCF506osimertinib + NXP900Tagrisso + eCF506Tagrisso + NXP900
02
Targets
EGFR (Epidermal growth factor receptor)SRC (Proto-oncogene tyrosine-protein kinase Src)YES1 (YES proto-oncogene 1 tyrosine kinase)
Beyond the preview
Go deeper on NXP900 + osimertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NXP900 + osimertinib.